JP2016515098A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515098A5
JP2016515098A5 JP2015560285A JP2015560285A JP2016515098A5 JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5 JP 2015560285 A JP2015560285 A JP 2015560285A JP 2015560285 A JP2015560285 A JP 2015560285A JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
dimethyl
carbazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515098A (ja
JP6395731B2 (ja
Filing date
Publication date
Priority claimed from US14/190,477 external-priority patent/US9492460B2/en
Application filed filed Critical
Publication of JP2016515098A publication Critical patent/JP2016515098A/ja
Publication of JP2016515098A5 publication Critical patent/JP2016515098A5/ja
Application granted granted Critical
Publication of JP6395731B2 publication Critical patent/JP6395731B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560285A 2013-02-27 2014-02-27 ブロモドメイン阻害剤として有用なカルバゾール化合物 Active JP6395731B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361769996P 2013-02-27 2013-02-27
US61/769,996 2013-02-27
US14/190,477 2014-02-26
US14/190,477 US9492460B2 (en) 2013-02-27 2014-02-26 Carbazole compounds useful as bromodomain inhibitors
PCT/US2014/018820 WO2014134232A1 (en) 2013-02-27 2014-02-27 Carbazole compounds useful as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
JP2016515098A JP2016515098A (ja) 2016-05-26
JP2016515098A5 true JP2016515098A5 (cg-RX-API-DMAC7.html) 2017-03-30
JP6395731B2 JP6395731B2 (ja) 2018-09-26

Family

ID=50382555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560285A Active JP6395731B2 (ja) 2013-02-27 2014-02-27 ブロモドメイン阻害剤として有用なカルバゾール化合物

Country Status (10)

Country Link
US (1) US9492460B2 (cg-RX-API-DMAC7.html)
EP (1) EP2961748B1 (cg-RX-API-DMAC7.html)
JP (1) JP6395731B2 (cg-RX-API-DMAC7.html)
CN (1) CN105008352B (cg-RX-API-DMAC7.html)
BR (1) BR112015020389A8 (cg-RX-API-DMAC7.html)
CA (1) CA2902737A1 (cg-RX-API-DMAC7.html)
EA (1) EA027345B1 (cg-RX-API-DMAC7.html)
ES (1) ES2669189T3 (cg-RX-API-DMAC7.html)
MX (1) MX2015010921A (cg-RX-API-DMAC7.html)
WO (1) WO2014134232A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2802608A4 (en) 2012-01-12 2015-08-05 Univ Yale COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
CN105189488B (zh) 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
JP6401773B2 (ja) * 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Betブロモドメイン阻害剤およびこれを用いる治療方法
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
HRP20200854T1 (hr) 2013-06-21 2020-08-21 Zenith Epigenetics Ltd. Novi biciklički inhibitori bromodomene
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
AR096837A1 (es) 2013-07-08 2016-02-03 Incyte Corp Heterociclos tricíclicos como inhibidores de proteínas bet
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規キナゾリノン
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EA032469B1 (ru) * 2013-12-24 2019-05-31 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
EP3110818B1 (en) 2014-02-28 2019-10-23 The Regents of The University of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MY207899A (en) 2014-04-23 2025-03-27 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
RU2016147946A (ru) 2014-05-08 2018-06-08 Онкоэтикс Гмбх Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
AU2015326910B2 (en) * 2014-10-02 2018-03-01 Glaxosmithkline Intellectual Property (No.2) Limited Compound
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
WO2016097863A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Inhibitors of bromodomains
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016183114A1 (en) * 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) * 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) * 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
WO2017165139A1 (en) 2016-03-25 2017-09-28 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor
EP3436006B1 (en) 2016-03-30 2025-07-30 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
DK3472157T3 (da) 2016-06-20 2023-05-01 Incyte Corp Krystallinske faste former af en bet-inhibitor
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
CR20220353A (es) 2019-12-19 2022-10-20 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111809182B (zh) * 2020-07-08 2025-04-18 江苏和达电子科技有限公司 一种用于铜/钼(铌)/igzo膜层的刻蚀液及其制备方法和应用
US12016847B2 (en) 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
EP4525863A1 (en) * 2022-05-20 2025-03-26 University Of Puerto Rico 1,4,5-trisubstituted-1,2,3-triazoles and uses thereof
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
DE60130891T2 (de) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
US6933313B2 (en) * 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
EP1677786A1 (en) 2003-10-18 2006-07-12 Bayer HealthCare AG 5-substituted 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
NZ599258A (en) * 2009-11-05 2014-05-30 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
CA2796967C (en) 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP5623996B2 (ja) 2010-09-21 2014-11-12 株式会社半導体エネルギー研究所 カルバゾール誘導体
JP5842630B2 (ja) 2011-03-16 2016-01-13 株式会社リコー カルバゾール誘導体、及び半導体ナノ結晶
EP2694619A4 (en) * 2011-05-03 2014-10-22 Rohm & Haas Elect Mat NEW ORGANIC ELECTROLUMINESCENSE COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE THEREWITH
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4

Similar Documents

Publication Publication Date Title
JP2016515098A5 (cg-RX-API-DMAC7.html)
TWI579284B (zh) 咪唑并吡咯啶酮化合物
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
JP2024517695A (ja) 複素環式化合物及び使用方法
RU2665036C2 (ru) Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения
CN111601593B (zh) P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
JP2025508702A (ja) キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
JP6935415B2 (ja) 2−アミノ−N−[7−メトキシ−2,3−ジヒドロイミダゾ−[1,2−c]キナゾリン−5−イル]ピリミジン−5−カルボキサミド類
RU2672910C9 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
WO2016203404A1 (en) Compounds and compositions for inhibiting the activity of shp2
JP2017524702A5 (cg-RX-API-DMAC7.html)
JP2017505762A5 (cg-RX-API-DMAC7.html)
JP2016530283A5 (cg-RX-API-DMAC7.html)
JP2012532131A5 (cg-RX-API-DMAC7.html)
JP2016523974A5 (cg-RX-API-DMAC7.html)
JP2014518544A5 (cg-RX-API-DMAC7.html)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
JP2016537384A5 (cg-RX-API-DMAC7.html)
EP3274344A1 (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors
JP2016509056A5 (cg-RX-API-DMAC7.html)
RU2014126750A (ru) Ингибиторы тирозинкиназы брутона
FI3478284T3 (fi) Yhdisteitä ja koostumuksia syövän hoitoon
WO2016193955A1 (en) Combinations of kinase inhibitors for treating colorectal cancer